Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Driver in fatal 2022 Halloween bus crash sentenced to 4 1/2 years in prison
The driver of a vehicle that struck a school bus, killing two of his friends and... -
Police: Pedestrian killed in Wood Dale
The pedestrian, a 31-year-old man later identified as Jorge Velasquez of Bensenville, was pronounced dead at... -
From ‘ghost town’ to boom town: How Arlington Alfresco kept downtown thriving
The co-owners of Hey Nonny in Arlington Heights faced financial difficulties when COVID-19 forced their business...